Stevanato Group (NYSE:STVN) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Stevanato Group (NYSE:STVN) announced its quarterly earnings results on Tuesday. The company reported €0.16 earnings per share for the quarter, topping analysts’ consensus estimates of €0.15 by €0.01, Zacks reports. Stevanato Group had a net margin of 11.76% and a return on equity of 10.27%. Stevanato Group updated its FY 2026 guidance to 0.700-0.720 EPS.

Here are the key takeaways from Stevanato Group’s conference call:

• Second-quarter revenue rose 8% to €302 million, while high-value solutions grew 16% and reached 45% of total revenue. Adjusted EBITDA increased 21% to €78.7 million, with the margin expanding to 26%.
• Demand remained strong for biologics, GLP-1 therapies, and integrated drug-delivery systems. European regulatory approvals for the Alina variable-dose pen, incorporating Stevanato’s cartridge technology, could support double-digit Alina revenue growth in coming years.
• The company raised the quality of its revenue mix through growth in premium Nexa and Alba syringes and EZ-fill vials, while Fishers and Latina continued to ramp. Fishers expects customer validation of its first EZ-fill vial line soon and commercial device production later in 2026.
• Stevanato completed the divestiture of Balda C. Brewer, reducing 2026 revenue by roughly €15 million but expected to improve full-year margins. The sale generated €12.2 million in one-time expenses and contributed to lower reported operating profit and net income in the quarter.
• The Engineering segment’s revenue declined 2%, and management cautioned that elongated sales cycles and project phasing remain risks despite improving margins and new orders. Quarterly free cash flow was negative €32 million, reflecting €52 million of capital expenditures, while full-year free cash flow guidance remains only breakeven to positive €20 million.

Stevanato Group Stock Down 5.4%

Shares of STVN stock traded down €1.11 on Tuesday, hitting €19.48. The stock had a trading volume of 316,076 shares, compared to its average volume of 540,130. The firm has a market capitalization of $5.90 billion, a price-to-earnings ratio of 33.16, a P/E/G ratio of 1.77 and a beta of 0.77. The stock’s 50 day moving average is €18.66 and its 200-day moving average is €16.97. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.11 and a current ratio of 1.63. Stevanato Group has a 52-week low of €12.89 and a 52-week high of €28.00.

Insider Activity

In related news, Director William J. Federici sold 1,493 shares of Stevanato Group stock in a transaction on Monday, June 15th. The shares were sold at an average price of €17.09, for a total transaction of €25,515.37. Following the sale, the director owned 26,991 shares of the company’s stock, valued at €461,276.19. The trade was a 5.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Karen Flynn sold 1,493 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of €17.09, for a total transaction of €25,515.37. Following the completion of the transaction, the director owned 5,757 shares in the company, valued at €98,387.13. This represents a 20.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 5,972 shares of company stock worth $102,061.

Institutional Trading of Stevanato Group

A number of hedge funds and other institutional investors have recently modified their holdings of STVN. GW&K Investment Management LLC boosted its holdings in Stevanato Group by 76.2% in the fourth quarter. GW&K Investment Management LLC now owns 2,440 shares of the company’s stock valued at $49,000 after purchasing an additional 1,055 shares during the last quarter. State of Wyoming grew its stake in Stevanato Group by 39,216.7% during the 2nd quarter. State of Wyoming now owns 2,359 shares of the company’s stock valued at $58,000 after purchasing an additional 2,353 shares in the last quarter. Quantbot Technologies LP purchased a new stake in Stevanato Group during the 3rd quarter worth approximately $68,000. Tower Research Capital LLC TRC increased its holdings in Stevanato Group by 1,268.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,585 shares of the company’s stock worth $112,000 after purchasing an additional 4,250 shares during the last quarter. Finally, Walleye Capital LLC acquired a new position in shares of Stevanato Group in the 4th quarter valued at approximately $214,000.

Wall Street Analyst Weigh In

Several research analysts have commented on STVN shares. Weiss Ratings raised Stevanato Group from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 16th. TD Cowen upgraded Stevanato Group to a “strong-buy” rating in a research note on Wednesday, June 17th. Finally, Wolfe Research started coverage on Stevanato Group in a report on Tuesday, June 2nd. They set an “outperform” rating and a $21.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, Stevanato Group currently has a consensus rating of “Buy”.

Stevanato Group Company Profile

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.